Abbvie Inc [ABBV] stock is trading at $189.02, down -0.15%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABBV shares have lost -0.95% over the last week, with a monthly amount drifted -0.51%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbvie Inc [NYSE: ABBV] stock has seen the most recent analyst activity on May 14, 2025, when Citigroup downgraded its rating to a Neutral but kept the price target unchanged to $205 for it. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on April 22, 2025, and set its price target to $210. Daiwa Securities downgraded its rating to a Neutral but stick to its price target of $180 on December 05, 2024. Leerink Partners upgraded its rating to a Outperform but $206 remained the price target by the analyst firm on November 22, 2024. Wolfe Research started tracking with a Outperform rating for this stock on November 15, 2024, and assigned it a price target of $205. In a note dated November 04, 2024, Argus upgraded an Buy rating on this stock.
Abbvie Inc [ABBV] stock has fluctuated between $163.81 and $218.66 over the past year. Currently, Wall Street analysts expect the stock to reach $217.5 within the next 12 months. Abbvie Inc [NYSE: ABBV] shares were valued at $189.02 at the most recent close of the market. An investor can expect a potential return of 15.07% based on the average ABBV price forecast.
Analyzing the ABBV fundamentals
Abbvie Inc [NYSE:ABBV] reported sales of 58.33B for the trailing twelve months, which represents a growth of 6.65%. Gross Profit Margin for this corporation currently stands at 0.36% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.86 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 49.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 184.82 points at the first support level, and at 180.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 196.02, and for the 2nd resistance point, it is at 203.03.
Ratios To Look Out For
For context, Abbvie Inc’s Current Ratio is 0.76. On the other hand, the Quick Ratio is 0.64, and the Cash Ratio is 0.14. Considering the valuation of this stock, the price to sales ratio is 5.72, the price to book ratio is 235.11 and price to earnings (TTM) ratio is 89.71.
Transactions by insiders
Recent insider trading involved Stewart Jeffrey Ryan, EVP, CHIEF COMMERCIAL OFFICER, that happened on Mar 31 ’25 when 58832.0 shares were sold. Officer, Stewart Jeffrey Ryan completed a deal on Mar 31 ’25 to buy 58832.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Reents Scott T sold 17644.0 shares on Mar 14 ’25.
